Qureight raises $20M in Series B to expand its AI-driven imaging research platform for cardiopulmonary clinical trials.
Key Details
- 1Qureight raised $20 million in Series B funding.
- 2The company is based in the UK and focuses on lung and heart disease clinical trials.
- 3Their platform offers AI-derived quantitative imaging biomarkers and CRO services.
- 4The technology is already used by biopharmas for trials involving fibrotic lung diseases.
- 5Funds will support an AI imaging lab built around 3D deep learning for chest imaging.
- 6Qureight plans expansion into diseases like asthma, pulmonary hypertension, and drug-induced lung toxicity.
Why It Matters
Qureight's enhanced platform and new imaging lab may accelerate development and deployment of AI biomarkers for a range of lung and heart diseases. This supports more efficient clinical trials and fosters broader application of imaging AI in drug development and disease monitoring.
Source
Radiology Business
Related News
•Radiology Business
CARPL.ai Raises $10M to Expand Radiology AI Marketplace
CARPL.ai secured $10M in Series A funding to expand its global radiology AI marketplace.
•Radiology Business
AI-Powered Tool Streamlines CT Scan Prioritization in Emergency Departments
An AI-based CT queue system significantly reduces wait times for ED patients by prioritizing scans likely to reveal critical findings.
•AuntMinnie
Radiologists Struggle to Spot AI-Generated Radiology Images
Radiologists correctly identify AI-generated images 75% of the time, with CT and MRI images being particularly challenging to spot.